Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Participants (N=10/group) will consist of non-treatment seeking individuals with AUD.
Following informed consent and baseline screening, participants will partake in 3 stress
induction sessions to assess their stress levels and cravings for alcohol. Participants will
be randomized to receive either increasing doses of doxazosin XL (0, 4, and 8 mg) or placebo
in a double-blind manner.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston